HLA Peptide Development as a Therapeutic for Psoriasis

HLA 肽开发用于治疗牛皮癣

• 批准号: 212989
• 负责人: Booth Valerie K
• 金额: $ 11.43万
• 依托单位: Memorial University of Newfoundland
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2010
• 资助国家: 加拿大
• 起止时间: 2010-09-01 至 2011-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=212989&lang=en
• 关键词: Hla-Cw6; Kir2ds1; Natural Killer Cell; Peptide Therapeutic; Psoriasis; Rational Drug Design

Psoriasis is a chronic skin disease that affects an estimated 1 to 3 % of the world's population. Psoriasis has been shown to affect health-related quality of life to an extent similar to the effects of other chronic diseases and has been linked to rheum

牛皮癣是一种慢性皮肤病，估计有1%到3%的世界人口受到影响。银屑病已被证明影响与健康相关的生活质量，其程度与其他慢性病的影响相似，并与风湿有关。